So, after a bunch of analysis and IR materials review, I finally created my custom small-cap/clinical stage Biotech basket. These are small plays that I believe have a better than average chance to successfully bring new and innovative therapies to market (or prove they work). Not for the faint of heart due to capital raises, dilution, and the risks of drug development. However, if even a few of these hit, the reward would be significant:
NTLA = Intellia Therapeutics (already mentioned)
CLRB = Cellectar Biosciences (already mentioned)
VYGR = Voyager Therapeutics
PRME = Prime Medicines
VTGN = Vistagen Therapeutics
COYA = Coya Therapeutics
CRBU = Caribou Biosciences
Happy to chat more about any of these, if interested.